Systemic therapy of disseminated malignant melanoma: An evidence-based overview of the state-of-the-art in daily routine

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 10, 2007, Pages 1305-1318

  Nashan, Dorothee ^a   Muller M L ^a   Grabbe, S ^b   Wustlich, S ^c   Enk, A ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c Dermatological Practice ^*  (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anti neoplastic mono and combined chemotherapy protocols; Evidence based medicine; Melanoma therapy; Review literature

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIESTROGEN; BLEOMYCIN; CANCER VACCINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DOCETAXEL; FOTEMUSTINE; HISTAMINE; HYDROXYUREA; INTERLEUKIN 2; LOMUSTINE; MAXAMINE; NITROSOUREA; OBLIMERSEN; PACLITAXEL; PEGINTERFERON; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; TEMOZOLOMIDE; TREOSULFAN; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ALOPECIA; ARTHRALGIA; ARTICLE; BLISTER; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BUDD CHIARI SYNDROME; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CARDIOPULMONARY INSUFFICIENCY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DISSEMINATED CANCER; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; ERYTHEMA; EVIDENCE BASED PRACTICE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; INTERNET; LEUKOPENIA; LUNG EMBOLISM; LUNG TOXICITY; MELANOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SKIN NECROSIS; SKIN TOXICITY; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URTICARIA;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; DACARBAZINE; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; MELANOMA; NEOPLASM METASTASIS; PROGNOSIS;

EID: 35648985218     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02475.x     Document Type: Article

References (173)

1. Ho VC, Sober AJ. Therapy for cutaneous melanoma: An update. J Am Acad Dermatol 1990; 22: 159-176.
2. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
3. Petro A, Schwartz J, Johnson T. Current melanoma staging. Clin Dermatol 2004; 22: 223-227.
4. Klimek VM, Wolchok JD, Chapman PB, Houghton AN, Hwu WJ. Systemic chemotherapy. Clin Plast Surg 2000; 27: 451-461.
5. Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: Results of a meta-analysis. Melanoma Res 2000; 10: 81-92.
6. Tilgen W. Adjuvante und palliative Therapie des Melanoms. Chirurg 1994; 65: 153-163. Ref Type: Journal (Full).
7. Agarwala SS. Chemotherapy Foundation Symposium XVIII. Session on malignant melanoma. Expert Opin Invest Drugs 2001; 10: 381-385.
8. Enk AH, Nashan D, Knop J. Treatment of lung metastases from malignant melanoma with IL-2 inhalation therapy. Hautarzt 1997; 48: 894-896.
9. Rehberger P, Eppinger S, Stein A, Schmitt J. Therapy of cutaneous metastases of malignent melanoma. Hautarzt 2006; 57: 1143-1153.
10. Fathallah-Shaykh HM, Zimmerman C, Morgan H, Rushing E, Schold SC Jr., Unwin DH. Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2. A case report. Cancer 1996; 77: 1544-1550.
11. Gutman M, Abu-Abid S, Sorkine P et al. Regional perfusion with hemofiltration (chemofiltration) for the treatment of patients with regionally advanced cancer. Cancer 1996; 78: 1125-1130.
12. Nakayama J, Takeuchi M, Mayumi H et al. Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion and concomitant infusion of either carboplatin or beta-interferon. J Dermatol 1996; 23: 6-15.
13. Strobbe LJ, Hart AA, Rumke P, Israels SP, Nieweg OE, Kroon BB. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res 1997; 7: 507-512.
14. Pubmed. URL: http://www.pubmed.gov (last accessed 29 March 2007).
15. Embase. URL: http://www.embase.com/ (last accessed 29 March 2007).
16. CancerLit. URL: http://www.cancer.gov/search/cancer_literature/ (last accessed 29 March 2007).
17. Oncolink. URL: http://www.oncolink.upenn.edu/ (last accessed 29 March 2007).
18. Cochrane Library. URL: http://www.update-software.com/cochrane/ (last accessed 29 March 2007).
19. American Society of Clinical Oncology. URL: http://www.asco.org (last accessed 29 March 2007).
20. National Cancer Institute (NCI). http://www.nci.nih.gov/ (last accessed 29 March 2007).
21. M. D. Anderson. Cancer Center. URL: http://www.mdanderson.org/ (last accessed 29 March 2007).
22. Deutsche Krebsgesellschaft e. V. URL: http://www.krebsgesellschaft.de/ (last accessed 29 March 2007).
23. Arbeitsgemeinschaft für Dermatologische Onkologie. URL: http://www.ado-homepage.de/ (last accessed 29 March 2007).
24. Roberts DL, Anstey AV, Barlow RJ et al.; British Association of Dermatologists; Melanoma Study Group. UK guidelines for the management of cutaneous melanoma. Br J Dermatol 2002; 146: 7-17.
25. Dummer R, Bosch U, Panizzon R, Bloch PH, Burg G. Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2001; 203: 75-80.
26. Bandolier Journal. URL: http://www.jr2.ox.ac.uk/bandolier/journal.html (last accessed 29 March 2007).
27. Centre for Evidence-Base Medicine. URL: http://www.cebm.utoronto.ca/ (last accessed 29 March 2007).
28. Guyatt GH, Sinclair J, Cook DJ, Glasziou P. Users' guides to the medical literature. XVI. How to use a treatment recommendation. Evidence-Based Med Working Group Cochrane Applicability Meth Working Group. JAMA 1999; 281: 1836-1843.
29. Levels of Evidence and Grades of Recommendation. URL: http://www.cebm.net/levels_of_evidence.asp (last accessed 29 March 2007).
30. Johnson TM, Smith JW, Nelson BR, Chang A. Current therapy for cutaneous melanoma. J Am Acad Dermatol 1995; 32: 689-707.
31. McClay EF, McClay ME. Systemic Chemotherapy for the tratment of metastatic melanoma. Semin Oncol 1996; 23: 744-753.
32. Ceci G, Bella M, Melissari M, Gabrielli M, Bocchi P, Cocconi G. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? Cancer 1988; 61: 1988-1991.
33. Bleehen NM, Newlands ES, Lee SM et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995; 13: 910-913.
34. Danson SJ, Middleton MR. Temozolomide: A novel oral alkylating agent. Expert Rev Anticancer Ther 2001; 1: 13-19.
35. Brada M, Judson I, Beale P et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999; 81: 1022-1030.
36. Hammond LA, Eckardt JR, Baker SD et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999; 17: 2604-2613.
37. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000; 5: 144-151.
38. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
39. Kaufmann R, Spieth K, Leiter U et al.; Dermatologic Cooperative Oncology Group. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: A randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005; 23: 9001-9007.
40. Agarwala SS, Kirkwood JM. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: A phase I dose-escalation study. Cancer 2003; 97: 121-127.
41. Richtig E, Hofmann-Wellenhof R, Pehamberger H et al. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV. Br J Dermatol 2004; 151: 91-98.
42. Emmert S, Zutt M, Haenssle H, Neumann C, Kretschmer L. Inefficacy of vindesine monotherapy in advanced stage IV malignant melanoma patients previously treated with other chemotherapeutic agents. Melanoma Res 2003; 13: 299-302.
43. Abbott KL, Harman GS. Combination chemotherapy for disseminated malignant melanoma. Anticancer Drugs 1995; 6: 489-497.
44. Jacquillat C, Khayat D, Banzet P et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66: 1873-1878.
45. Khayat D, Avril MF, Gerard B, Bertrand P, Bizzari JP, Cour V. Fotemustine: An overview of its clinical activity in disseminated malignant melanoma. Melanoma Res 1992; 2: 147-151.
46. Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol 2004; 22: 1118-1125.
47. Petit T, Borel C, Rixe O et al. Complete remission seven years after treatment for metastatic malignant melanoma. Cancer 1996 1; 77: 900-902.
48. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer 1990; 65: 2478-2481.
49. Einzig AI, Hochster H, Wiernik PH et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9: 59-64.
50. Bedikian AY, Weiss GR, Legha SS et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 1995; 13: 2895-2899.
51. Gogas H, Bafaloukos D, Bedikian AY. The role of taxanes in the treatment of metastatic melanoma. Melanoma Res 2004; 14: 415-420.
52. Neuber K, tom DA, Blodorn-Schlicht N, Itschert G, Karnbach C. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo. Melanoma Res 1999; 9: 125-132.
53. Agarwala SS, Hellstrand K, Naredi P. Interleukin-2 and histamine dihydrochloride in metastatic melanoma. J Clin Oncol 2002; 20: 3558-3559.
54. Agarwala SS, Glaspy J, O'Day SJ et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002; 20: 125-133.
55. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75-81.
56. Bajetta E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994; 12: 806-811.
57. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738-4745.
58. Chiarion-Sileni V, Nortilli R, Medici M. BCNU, cisplatin dacarbazine and tamoxifen in metastatic melanoma: Results of a randomized Phase II study. Proc Am Soc Clin Oncol 1997; 16: A1782.
59. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-2751.
60. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1403-1408.
61. Falkson CI. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma. Med Oncol 1995; 12: 35-40.
62. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 1743-1751.
63. Thomson DB, Adena M, McLeod GR et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: Results of a multi-institutional Australian randomized trial. Melanoma Res 1993; 3: 133-138.
64. Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol) 2001; 13: 458-465.
65. Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC Study Group of the DeCOG. Ann Oncol 2006; 17: 563-570.
66. Cohen SM, Greenspan EM, Ratner LH, Weiner MJ. Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine. Cancer 1977; 39: 41-44.
67. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984; 68: 1403-1405.
68. McClay EF, Mastrangelo MJ, Bellet RE, Berd D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987; 71: 465-469.
69. Gundersen S. Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: A phase II study. Cancer Treat Rep 1987; 71: 997-999.
70. Seigler HF, Lucas VS Jr, Pickett NJ, Huang AT. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer 1980; 46: 2346-2348.
71. Jelic S, Babovic N, Kovcin V et al. Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: A single-centre randomized four-arm study. Melanoma Res 2002; 12: 91-98.
72. Chiarion-Sileni V, Nortilli R, Aversa SM et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 2001; 11: 189-196.
73. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years? Eur J Cancer 2004; 40: 1825-1836.
74. Avril MF, Bonneterre J, Delaunay M et al. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience French Study Group. Cancer Chemother Pharmacol 1990; 27: 81-84.
75. Merimsky O, Chaitchik S. Fotemustine-dacarbazine combinations in the treatment of metastatic melanoma. Eur J Cancer 1993; 29A: 481-482.
76. Aamdal S, Gerard B, Bohman T, D'Incalci M. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma - an effective combination with unexpected toxicity. Eur J Cancer 1992; 28: 447-450.
77. Seeber A, Binder M, Steiner A, Wolff K, Pehamberger H. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. Eur J Cancer 1998; 34: 2129-2131.
78. Bafaloukos D, Tsoutsos D, Kalofonos H et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: A randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16: 950-957.
79. Weichenthal M, Mohr P, Stephan U et al. Fotemustine and interferon alpha2b in metastatic malignant melanoma. J Cancer Res Clin Oncol 1998; 124: 55-59.
80. European Organisation for Research and Treatment of Cancer. URL: http://www.eortc.be/default.htm (last accessed 29 March 2007).
81. Rumke P, Kleeberg UR, MacKie RM et al. Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group. Melanoma Res 1992; 2: 153-156.
82. Kleeberg UR, Engel E, Brocker EB et al. Effect of Toremifene in patients with metastatic melanoma: A phase II study of the EORTC Melanoma Cooperative Group. Melanoma Res 1993; 3: 123-126.
83. Creagan ET, Schutt AJ, Ahmann DL, Green SJ. Phase II study of high-dose megestrol acetate in patients with advanced malignant melanoma. Cancer Treat Rep 1982; 66: 1239-1240.
84. Nathanson L, Meelu MA, Losada R. Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin. Cancer 1994; 73: 98-102.
85. Cocconi G, Bella M, Calabresi F et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327: 516-523.
86. Flaherty LE, Liu PY, Mitchell MS et al. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921). Am J Clin Oncol 1996; 19: 108-113.
87. McClay EF, Mastrangelo MJ, Sprandio JD, Bellet RE, Berd D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989; 63: 1292-1295.
88. McClay EF, Albright KD, Jones JA et al. Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 1992; 52: 6790-6796.
89. McClay EF, Mastrangelo MJ, Berd D, Bellet RE. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials. Int J Cancer 1992; 50: 553-556.
90. McClay EF, Albright KD, Jones JA, Christen RD, Howell SB. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 1993; 53: 1571-1576.
91. Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 1999; 85: 1979-1984.
92. Creagan ET, Suman VJ, Dalton RJ et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol, 1999; 17: 1884-1890.
93. Rusthoven JJ, Quirt IC, Iscoe NA et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2083-2090.
94. Lattanzi SC, Tosteson T, Chertoff J et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 1995; 5: 365-369.
95. O'Day SJ, Kim CJ, Reintgen DS. Metastatic melanoma: Chemotherapy to biochemotherapy. Cancer Control 2002; 9: 31-38.
96. Kirkwood JM. Studies of interferons in the therapy of melanoma. Semin Oncol 1991; 18 (5 Suppl. 7): 83-90.
97. Ho RC. Medical management of stage IV malignant melanoma. Medical issues. Cancer 1995; 75 (2 Suppl.): 735-741.
98. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10: 1338-1343.
99. Eggermont AM. The role interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer 2001; 37: 2147-2153.
100. Dummer R, Garbe C, Thompson JA et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006; 24: 1188-1194.
101. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-2116.
102. Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 1996; 77: 89-96.
103. Wolkenstein P, Chosidow O, Wechsler J et al. Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma. J Am Acad Dermatol 1993; 28: 66-70.
104. Buzaid AC, Atkins M. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Clin Cancer Res 2001; 7: 2611-2619.
105. Karp SE. Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma. J Immunother 1998; 21: 56-61.
106. Atzpodien J, Korfer A, Evers P et al. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: A phase II outpatient study. Mol Biother 1990; 2: 18-26.
107. Eton O, Rosenblum MG, Legha SS et al. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer 2002; 95: 127-134.
108. de Gast GC, Klumpen HJ, Vyth-Dreese FA et al. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 2000; 6: 1267-1272.
109. Keilholz U, Stoter G, Punt CJ et al. Recombinant interleukin-2-based treatments for advanced melanoma. the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am 1997; 3 (Suppl. 1): S22-S28.
110. Keilholz U, Goey SH, Punt CJ et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15: 2579-2588.
111. Keilholz U, Conradt C, Legha SS et al. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 1998; 16: 2921-2929.
112. Margolin KA, Doroshow JH, Akman SA et al. Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma. J Clin Oncol 1992; 10: 1574-1578.
113. Mulder NH, de Vries EG, Sleijfer DT, Schraffordt KH, Willemse PH. Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma. Br J Cancer 1992; 65: 303-304.
114. Gundersen S, Flokkmann A. Interferon plus dacarbazine in advanced malignant melanoma: A phase I-II study. Eur J Cancer 1991; 27: 220-221.
115. Gundersen S, Flokkmann A. Interferon in combination with vinblastine in advanced malignant melanoma. A Phase I-II study. Cancer 1989; 64: 1617-1619.
116. Feun LG, Savaraj N, Moffat F et al. Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. Melanoma Res 1995; 5: 273-276.
117. Bafaloukos D, Pavlidis N, Fountzilas G et al. Recombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma. Am J Clin Oncol 1996; 19: 296-300.
118. Schultz MZ, Buzaid AC, Poo WJ. A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. Melanoma Res 1997; 7: 147-151.
119. Atkins MB, O'Boyle KR, Sosman JA et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994; 12: 1553-1560.
120. Demchak PA, Mier JW, Robert NJ et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: A pilot study. J Clin Oncol 1991; 9: 1821-1830.
121. Dummer R, Gore ME, Hancock BW et al. A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer 1995; 75: 1038-1044.
122. Flaherty LE, Robinson W, Redman BG et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993; 71: 3520-3525.
123. Hauschild A, Garbe C, Stolz W et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: A randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001; 84: 1036-1042.
124. Dorval T, Negrier S, Chevreau C et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: A Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 1999; 85: 1060-1066.
125. Middleton MR, Lorigan P, Owen J et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82: 1158-1162.
126. Daponte A, Ascierto PA, Gravina A et al. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. Cancer 2000; 89: 2630-2636.
127. Guida M, Latorre A, Mastria A, De Lena M. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma. Eur J Cancer 1996; 32A: 730-733.
128. Khayat D, Borel C, Tourani JM et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993; 11: 2173-2180.
129. Schmidt H, Geertsen PF, Fode K et al. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: A phase II study. Melanoma Res 2000; 10: 66-77.
130. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17: 968-975.
131. Flaherty LE, Atkins M, Sosman J et al. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: Results of two phase II cytokine Working Group trials. J Clin Oncol 2001; 19: 3194-3202.
132. Keilholz U, Punt CJ, Gore M et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23: 6747-6755.
133. Ridolfi R, Chiarion-Sileni V, Guida M et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: Results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002 15; 20: 1600-1607.
134. Legha SS, Ring S, Bedikian A et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996; 7: 827-835.
135. Legha SS, Ring S, Eton O et al. Development and results of biochemotherapy in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 1997; 3 (Suppl. 1): S9-S15.
136. Eton O, Legha SS, Bedikian AY et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 2002; 20: 2045-2052.
137. Gibbs P, Iannucci A, Becker M et al. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma. Melanoma Res 2000; 10: 171-179.
138. Atkins M, Lee SM, Flaherty LE et al. A propspective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 2003; 22: 708.
139. Bajetta EVM, Nova P, Fusi A et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006; 17: 571-577.
140. Atzpodien J, Neuber K, Kamanabrou D et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: Results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002; 86: 179-184.
141. Kirchner HH, Atzpodien J, Poliwoda H. Chemo-/immunotherapy in advanced malignant melanoma. carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a. Med Klin (Munich) 1996; 91 (Suppl. 3): 44-49.
142. Johnston SR, Constenla DO, Moore J et al. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998; 77: 1280-1286.
143. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma. a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4: 748-759.
144. Eggermont AM. European approach to the treatment of malignant melanoma. Curr Opin Oncol 2002; 14: 205-211.
145. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351: 998-1012.
146. Flaherty LE. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma. Cancer J Sci Am 2000; 6 (Suppl. 1): S15-S20.
147. Keilholz U, Eggermont AM. The emerging role of cytokines in the treatment of advanced melanoma. For EORTC Melanoma Cooperative Group. Oncology 2000; 58: 89-95.
148. Eggermont AM. The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: Prognosis versus efficacy, toxicity and costs. Melanoma Res 1997; 7 (Suppl. 2): S127-S131.
149. Hauschild A. Protocol for optimal therapy of malignant melanoma in the metastatic stage by the Dermatologic Oncology Working Group. Hautarzt 1996; 47: 67-68.
150. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. J Exp Clin Cancer Res 2000; 19: 21-34.
151. McDermott DF, Mier JW, Lawrence DP et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res 2000; 6: 2201-2208.
152. O'Day SJ, Gammon G, Boasberg PD et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999; 17: 2752-2761.
153. Punt CJ, Suciu S, Gore MA et al. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. Eur J Cancer 2006; 42: 2991-2995.
154. Allen I, Kupelnick B, Kumashiro M. Efficacy of interleukin-2 in the treatment of metastatic melanoma -systemic review and metastasis analysis. Cancer Ther 1998; 1: 168-173.
155. Nemunaitis J, Fong T, Robbins JM et al. Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther 1999; 6: 322-330.
156. Kayaga J, Souberbielle BE, Sheikh N et al. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther 1999; 6: 1475-1481.
157. Arienti F, Sule-Suso J, Belli F et al. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 1996; 7: 1955-1963.
158. Palmer K, Moore J, Everard M et al. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther 1999; 10: 1261-1268.
159. Hersh EM, Stopeck AT. Advances in the biological therapy and gene therapy of malignant disease. Clin Cancer Res 1997; 3: 2623-2629.
160. Stopeck AT, Hersh EM, Akporiaye ET et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997; 15: 341-349.
161. Schreiber S, Kampgen E, Wagner E et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study. Hum Gene Ther 1999; 10: 983-993.
162. Trefzer U, Weingart G, Chen Y et al. Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma. Int J Cancer 2000; 85: 618-626.
163. Maio M, Parmiani G. Melanoma immunotherapy: New dreams or solid hopes? Immunol Today 1996; 17: 405-407.
164. McArthur JG, Mulligan RC. Induction of protective anti-tumor immunity by gene-modified dendritic cells. J Immunother 1998; 21: 41-47.
165. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332.
166. Livingston P. The unfulfilled promise of melanoma vaccines. Clin Cancer Res 2001; 7: 1837-1838.
167. Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC Study Group of the DeCOG. Ann Oncol 2006; 17: 563-570.
168. Barth A, Wanek LA, Morton DL. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193-201.
169. Guven K, Kittler H, Wolff K, Pehamberger H. Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients. Melanoma Res 2001; 11: 411-415.
170. Eapen S, Dutcher JP. A review of evidence-based treatment of stage IIB to stage IV melanoma. Cancer Invest 2005; 23: 323-337.
171. Tarhini AA, Agarwala SS. Cutaneous melanoma: Available therapy for metastatic disease. Dermatol Ther 2006; 19: 19-25.
172. Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic
173. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007; 109: 455-464.